Plasma sPD-L1 and VEGF levels are associated with the prognosis of NSCLC patients treated with combination...

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• The clinical utility of plasma soluble programmed cell death ligand 1 (sPD-L1) and vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC) treated with combined anti-angiogenic and anti-PD-L1 therapy is not well understood.
• Envafolimab and Endostar represent a combination therapy targeting PD-L1 and angiogenesis in NSCLC.

Purpose of the Study:

• To investigate the association between plasma sPD-L1 and VEGF levels and the prognosis of NSCLC patients undergoing treatment with Envafolimab and Endostar.
• To determine if baseline and post-treatment levels of these biomarkers correlate with treatment response and survival outcomes.

Main Methods:

• Collected peripheral blood samples from 24 NSCLC patients at baseline and after 6 weeks of treatment.
• Quantified plasma sPD-L1 and VEGF levels using appropriate assays.
• Analyzed the correlation between biomarker levels and clinical outcomes, including progressive disease (PD) and controlled disease (CD), and progression-free survival (PFS).

Main Results:

• Both baseline and post-treatment sPD-L1 levels were significantly higher in the PD group compared to the CD group.
• Lower baseline sPD-L1 levels were significantly associated with longer PFS.
• Post-treatment VEGF levels were significantly higher in the PD group than in the CD group.
• Higher post-treatment VEGF levels were significantly associated with shorter PFS.

Conclusions:

• Plasma sPD-L1 and VEGF levels serve as potential predictive biomarkers for clinical response and prognosis in NSCLC patients treated with a combination of PD-L1 inhibitors and anti-angiogenic therapy.
• These findings highlight the importance of monitoring sPD-L1 and VEGF in patients receiving this combined treatment regimen.